ClinicalTrials.gov record
Completed Phase 3 Interventional

A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides

ClinicalTrials.gov ID: NCT00134498

Public ClinicalTrials.gov record NCT00134498. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 10, 2026, 10:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia

Study identification

NCT ID
NCT00134498
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
160 participants

Conditions and interventions

Interventions

  • atorvastatin Drug
  • torcetrapib/atorvastatin Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2005
Primary completion
Not listed
Completion
Oct 31, 2006
Last update posted
Nov 15, 2007

2005 – 2006

United States locations

U.S. sites
39
U.S. states
23
U.S. cities
39
Facility City State ZIP Site status
Pfizer Investigational Site Anaheim California
Pfizer Investigational Site Huntington Beach California
Pfizer Investigational Site Los Angeles California
Pfizer Investigational Site Orange California
Pfizer Investigational Site Orangevale California
Pfizer Investigational Site Pacific Palisades California
Pfizer Investigational Site Studio City California
Pfizer Investigational Site Tustin California
Pfizer Investigational Site Walnut Creek California
Pfizer Investigational Site Farmington Connecticut
Pfizer Investigational Site Washington D.C. District of Columbia
Pfizer Investigational Site Hollywood Florida
Pfizer Investigational Site Longwood Florida
Pfizer Investigational Site West Palm Beach Florida
Pfizer Investigational Site Tripler AMC Hawaii
Pfizer Investigational Site Chicago Illinois
Pfizer Investigational Site Indianapolis Indiana
Pfizer Investigational Site Overland Park Kansas
Pfizer Investigational Site Baton Rouge Louisiana
Pfizer Investigational Site Scarborough Maine
Pfizer Investigational Site Bethesda Maryland
Pfizer Investigational Site Ann Arbor Michigan
Pfizer Investigational Site Canton Michigan
Pfizer Investigational Site Portage Michigan
Pfizer Investigational Site Richland Michigan
Pfizer Investigational Site Saint Cloud Minnesota
Pfizer Investigational Site Olive Branch Mississippi
Pfizer Investigational Site Jefferson City Missouri
Pfizer Investigational Site St Louis Missouri
Pfizer Investigational Site Las Vegas Nevada
Pfizer Investigational Site Rochester New York
Pfizer Investigational Site Syracuse New York
Pfizer Investigational Site West Seneca New York
Pfizer Investigational Site Statesville North Carolina
Pfizer Investigational Site Sellersville Pennsylvania
Pfizer Investigational Site Warwick Rhode Island
Pfizer Investigational Site San Antonio Texas
Pfizer Investigational Site Richmond Virginia
Pfizer Investigational Site Madison Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00134498, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 15, 2007 · Synced May 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00134498 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →